NVIDIA launches Jetson Thor robotics computers for physical AI systems
Holbrook Kerr, the Senior Vice President and Chief Commercial Officer of Avanos Medical (TASE:BLWV), Inc. (NYSE:AVNS), recently reported a sale of 7,000 shares of the company’s common stock. The transaction, which took place on March 6, 2025, was executed at an average price of $15.254 per share, amounting to a total value of approximately $106,778. The sale occurs as AVNS trades near its 52-week low, with InvestingPro analysis indicating the stock is currently undervalued. The company maintains strong liquidity with a current ratio of 2.37 and operates with moderate leverage.
Following this sale, Kerr holds 82,047 shares of Avanos Medical. Additionally, Kerr surrendered shares to satisfy tax withholding obligations related to the vesting of time-based restricted share units. These transactions involved 2,474 shares and 3,590 shares, respectively, valued at $15.30 per share, totaling $92,779. Get deeper insights into AVNS’s valuation metrics and 8 additional key ProTips with a subscription to InvestingPro, including exclusive access to comprehensive Pro Research Reports covering 1,400+ US stocks.
In other recent news, Avanos Medical Inc. reported impressive financial results for the fourth quarter of 2024, with both earnings per share (EPS) and revenue surpassing expectations. The company achieved an EPS of $0.43, outperforming the forecast of $0.40, while revenue reached $179.6 million, exceeding the anticipated $177.23 million. Avanos also announced the completion of the sale of its Respiratory Health business, marking a significant milestone in its transformation process. The company is focusing on long-term gross margins of over 60% and has set a net sales guidance for 2025 between $665 million and $685 million. Analysts have noted Avanos’ strategic focus on organic growth in its Specialty Nutrition Systems segment. Additionally, the company received notification from the Department of Justice regarding the fulfillment of commitments related to a deferred prosecution agreement. Avanos continues to pursue mergers and acquisitions in line with its transformation priorities. The company has also been highlighted for its efforts in cost transformation initiatives, which have improved efficiency and financial metrics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.